Therapeutic potential of the antimicrobial peptide oh-cath30 for antibiotic-resistant pseudomonas aeruginosa keratitis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3144-3150

  Li, Sheng An ^a   Liu, Jie ^a   Xiang, Yang ^a   Wang, Yan Jie ^a   Lee, Wen Hui ^a   Zhang, Yun ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOPERAZONE; CIPROFLOXACIN; GENTAMICIN; INTERLEUKIN 1BETA; LEVOFLOXACIN; OH CATH30; POLYPEPTIDE ANTIBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL KERATITIS; BACTERIAL LOAD; BROTH DILUTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TREATMENT OUTCOME; ANIMAL; DISEASE MODEL; DRUG EFFECTS; EYE INFECTIONS, BACTERIAL; HUMAN; KERATITIS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PSEUDOMONAS INFECTIONS; RABBIT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CIPROFLOXACIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; EYE INFECTIONS, BACTERIAL; GENTAMICINS; HUMANS; KERATITIS; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RABBITS;

EID: 84901281590     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00095-14     Document Type: Article

References (31)

1. Banin E, Lozinski A, Brady KM, Berenshtein E, Butterfield PW, Moshe M, Chevion M, Greenberg EP, Banin E. 2008. The potential of desferrioxamine-gallium as an anti-Pseudomonas therapeutic agent. Proc. Natl. Acad. Sci. U. S. A. 105:16761-16766. http://dx.doi.org/10.1073/pnas.0808608105.
2. Hazlett LD. 2004. Corneal response to Pseudomonas aeruginosa infection. Prog. Retin. Eye Res. 23:1-30. http://dx.doi.org/10.1016/j.preteyeres.2003.10. 002.
3. Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F. 2007. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin. Microbiol. Infect. 13:560-578. http://dx.doi.org/10.1111/j.1469-0691.2007.01681.x.
4. Sueke H, Kaye S, Neal T, Murphy C, Hall A, Whittaker D, Tuft S, Parry C. 2010. Minimum inhibitory concentrations of standard and novel antimicrobials for isolates from bacterial keratitis. Invest. Ophthalmol. Vis. Sci. 51:2519-2524. http://dx.doi.org/10.1167/iovs.09-4638.
5. Landman D, Bratu S, Kochar S, Panwar M, Trehan M, Doymaz M, Quale J. 2007. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumonide in Brooklyn, NY. J. Antimicrob. Chemother. 60:78-82. http://dx.doi.org/10.1093/jac/dkm129.
6. Chin JN, Jones RN, Sader HS, Savage PB, Rybak MJ. 2008. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. J. Antimicrob. Chemother. 61:365-370. http://dx.doi.org/10.1093/jac/dkm457.
7. Zasloff M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395. http://dx.doi.org/10.1038/415389a.
8. Wu M, Maier E, Benz R, Hancock RE. 1999. Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry 38: 7235-7242. http://dx.doi.org/10.1021/bi9826299.
9. Bals R, Wilson JM. 2003. Cathelicidins-A family of multifunctional antimicrobial peptides. Cell. Mol. Life Sci. 60:711-720. http://dx.doi.org/10. 1007/s00018-003-2186-9.
10. Habets MG, Brockhurst MA. 2012. Therapeutic antimicrobial peptides may compromise natural immunity. Biol. Lett. 8:416-418. http://dx.doi.org/10.1098/ rsbl.2011.1203.
11. Bayer AS, Schneider T, Sahl HG. 2013. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann. N. Y. Acad. Sci. 1277:139-158. http://dx.doi.org/10.1111/j.1749-6632.2012.06819.x.
12. Kolar SS, McDermott AM. 2011. Role of host-defense peptides in eye diseases. Cell. Mol. Life Sci. 68:2201-2213. http://dx.doi.org/10.1007/s00018- 011-0713-7.
13. Wu M, McClellan SA, Barrett RP, Hazlett LD. 2009. Beta-defensin-2 promotes resistance against infection with P. aeruginosa. J. Immunol. 182: 1609-1616.
14. Wu M, McClellan SA, Barrett RP, Zhang Y, Hazlett LD. 2009. Beta-defensins 2 and 3 together promote resistance to Pseudomonas aeruginosa keratitis. J. Immunol. 183:8054-8060. http://dx.doi.org/10.4049/jimmunol.0902140.
15. Huang LC, Reins RY, Gallo RL, McDermott AM. 2007. Cathelicidindeficient (Cnlp-/-) mice show increased susceptibility to Pseudomonas aeruginosa keratitis. Invest. Ophthalmol. Vis. Sci. 48:4498-4508. http://dx.doi.org/10. 1167/iovs.07-0274.
16. Yin J, Yu FS. 2010. LL-37 via EGFR transactivation to promote high glucose-Attenuated epithelial wound healing in organ-cultured corneas. Invest. Ophthalmol. Vis. Sci. 51:1891-1897. http://dx.doi.org/10.1167/iovs.09-3904.
17. Silva NC, Sarmento B, Pintado M. 2013. The importance of antimicrobial peptides and their potential for therapeutic use in ophthalmology. Int. J. Antimicrob. Agents 41:5-10. http://dx.doi.org/10.1016/j.ijantimicag.2012.07.020.
18. Nos-Barbera S, Portoles M, Morilla A, Ubach J, Andreu D, Paterson CA. 1997. Effect of hybrid peptides of cecropin A and melittin in an experimental model of bacterial keratitis. Cornea 16:101-106.
19. Mannis MJ. 2002. The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis. Trans. Am. Ophthalmol. Soc. 100:243-271.
20. Oo TZ, Cole N, Garthwaite L, Willcox MD, Zhu H. 2010. Evaluation of synergistic activity of bovine lactoferricin with antibiotics in corneal infection. J. Antimicrob. Chemother. 65:1243-1251. http://dx.doi.org/10.1093/ jac/dkq106.
21. Zhao H, Gan T-X, Liu X-D, Jin Y, Lee W-H, Shen J-H, Zhang Y. 2008. Identification and characterization of novel reptile cathelicidins from elapid snakes. Peptides 29:1685-1691. http://dx.doi.org/10.1016/j.peptides.2008.06.008.
22. Li SA, Lee WH, Zhang Y. 2012. Efficacy of OH-CATH30 and its analogs against drug-resistant bacteria in vitro and in mouse models. Antimicrob. Agents Chemother. 56:3309-3317. http://dx.doi.org/10.1128/AAC.06304-11.
23. Li SA, Xiang Y, Wang YJ, Liu J, Lee WH, Zhang Y. 2013. Naturally occurring antimicrobial peptide OH-CATH30 selectively regulates the innate immune response to protect against sepsis. J. Med. Chem. 56:9136-9145. http://dx.doi.org/10.1021/jm401134n.
24. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing, 19th informational supplement. CLSI document M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
25. Navon-Venezia S, Feder R, Gaidukov L, Carmeli Y, Mor A. 2002. Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob. Agents Chemother. 46:689-694. http://dx.doi.org/10.1128/AAC.46.3. 689-694.2002.
26. Stangogiannis-Druya E, Stangogiannis-Druya C, Naranjo-Tackman R, Vanzzini V, Villar-Kuri J. 2009. Bacterial corneal ulcer treated with intrastromal antibiotic. Experimental model in vivo. Arch. Soc. Esp. Oftalmol. 84:123-132. (In Spanish.) http://dx.doi.org/10.4321/S0365-66912009000300004.
27. Karicherla P, Hobden JA. 2009. Nona-D-Arginine therapy for Pseudomonas aeruginosa keratitis. Invest. Ophthalmol. Vis. Sci. 50:256-262. http://dx.doi.org/10.1167/iovs.08-2344.
28. Cassone M, Vogiatzi P, La Montagna R, De Olivier Inacio V, Cudic P, Wade JD, Otvos L, Jr. 2008. Scope and limitations of the designer proline-rich antibacterial peptide dimer, A3-APO, alone or in synergy with conventional antibiotics. Peptides 29:1878-1886. http://dx.doi.org/10.1016/j.peptides.2008. 07.016.
29. Lefebvre M, Jacqueline C, Amador G, Le Mabecque V, Miegeville A, Potel G, Caillon J, Asseray N. 2010. Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis. Int. J. Antimicrob. Agents 36:542-544. http://dx.doi.org/10.1016/j.ijantimicag.2010.07.008.
30. Cirioni O, Giacometti A, Silvestri C, Della Vittoria A, Licci A, Riva A, Scalise G. 2006. In vitro activities of tritrpticin alone and in combination with other antimicrobial agents against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:3923-3925. http://dx.doi.org/10.1128/AAC.00652-06.
31. Gifford JL, Hunter HN, Vogel HJ. 2005. Lactoferricin: a lactoferrinderived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell. Mol. Life Sci. 62:2588-2598. http://dx.doi.org/10.1007/s00018-005-5373-z.